A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis Under Conditions of Daily Practice
A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis Under Conditions of Daily Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safety parameters are measured routinely at baseline and after 3, 6, 9, 12, 18 and 24 months.
Inclusion:
Exclusion:
-None
Berlin-Weissensee, 13086, Germany
Blankenburg/Hart, 38889, Germany
Ingoldstadt, 85049, Germany
Leinefelde, 37327, Germany
Moenkeburg, 24248, Germany
Saint Martin, 67487, Germany
Ueberlingen-Nussdorf, 88662, Germany